Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.

Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.

Item
http://www.wikidata.org/entity/Q34605471
Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice.Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral TherapyGastrointestinal Symptoms in HIV-Infected Patients: Female Sex and Smoking as Risk Factors in an Outpatient Cohort in Brazil.Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.Prevalence of and risk for gastrointestinal bleeding and peptic ulcerative disorders in a cohort of HIV patients from a U.S. healthcare claims databaseHIV protease inhibitors in gut barrier dysfunction and liver injury.Human Immunodeficiency Virus-Associated Diarrhea: Still an Issue in the Era of Antiretroviral Therapy.Patient and provider-reported symptoms in the post-cART era.Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted ProtePatient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovirCrofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDSEffect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.Prevalence of gastrointestinal symptoms among ambulatory HIV patients and a control population.Gastrointestinal symptoms among ambulatory HIV patients: appropriate symptom management requires improved symptom recognition.Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc.Global impact of antiretroviral therapy-associated diarrhea.Reported health, lifestyle and clinical manifestations associated with HIV status in people from rural and urban communities in the Free State Province, South Africa.
P2860

Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.

Item
http://www.wikidata.org/entity/Q34605471
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.
@ast
Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.
@en
Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.
@nl
type
label
Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.
@ast
Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.
@en
Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.
@nl
prefLabel
Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.
@ast
Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.
@en
Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.
@nl
P1433
P1476
P2093
P304
P31
P433
P478
P577
P698
P1433
P1476
Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.
@en
P2093
P304
P31
P433
P478
P577
P698